JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Отворен

18.66 1.97

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.08

Максимум

19.75

Ключови измерители
By Trading Economics
Приходи	35M 9.5M
Продажби	35M 94M
Марж на печалбата	10.158
Служители	619
EBITDA	35M 17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+10.27% upside

Дивиденти
By Dow Jones
Следващи печалби	5.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	279M 2.9B
Предишно отваряне	16.69
Предишно затваряне	18.66

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2.02.2026 г., 23:28 ч. UTC

Пазарно говорене

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2.02.2026 г., 23:23 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2.02.2026 г., 22:57 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2.02.2026 г., 21:51 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.02.2026 г., 21:49 ч. UTC

Печалби

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2.02.2026 г., 21:39 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:36 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2.02.2026 г., 21:34 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 21:23 ч. UTC

Печалби

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2.02.2026 г., 21:19 ч. UTC

Печалби

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:10 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:08 ч. UTC

Печалби

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2.02.2026 г., 21:07 ч. UTC

Печалби

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Net $608.7M >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Rev $1.41B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Adj EPS 25c >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q EPS 24c >PLTR

2.02.2026 г., 20:40 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

10.27% нагоре

12-месечна прогноза

Среден 20.4 USD 10.27%

Висок 21 USD

Нисък 20 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.